|
|
|
 |
 |
 |
 |
 |
VH-404 Qualitative ParametersPublication Highlights derived from the VHI (funding acknowledged)Dietrich, S., H. Glimm, M. Andrulis, C. von Kalle, A. D. Ho and T. Zenz (2012). "BRAF inhibition in refractory hairy-cell leukemia." N Engl J Med 366(21): 2038-2040. IF 51.658 Knudsen, P. B., B. Hanna, S. Ohl, L. Sellner, T. Zenz, H. Dohner, S. Stilgenbauer, T. O. Larsen, P. Lichter and M. Seiffert (2013). "Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton." Leukemia. IF 10.164 Zenz, T., J. G. Gribben, M. Hallek, H. Dohner, M. J. Keating and S. Stilgenbauer (2012). "Risk categories and refractory CLL in the era of chemoimmunotherapy." Blood 119(18): 4101-4107. IF 9.060 Garding, A., N. Bhattacharya, R. Claus, M. Ruppel, C. Tschuch, K. Filarsky, I. Idler, M. Zucknick, M. Caudron-Herger, C. Oakes, V. Fleig, I. Keklikoglou, D. Allegra, L. Serra, S. Thakurela, V. Tiwari, D. Weichenhan, A. Benner, B. Radlwimmer, H. Zentgraf, S. Wiemann, K. Rippe, C. Plass, H. Dohner, P. Lichter, S. Stilgenbauer and D. Mertens (2013). "Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB." PLoS Genet 9(4): e1003373. IF 8.517 Oakes, C. C., R. Claus, L. Gu, Y. Assenov, J. Hullein, M. Zucknick, M. Bieg, D. Brocks, O. Bogatyrova, C. R. Schmidt, L. Rassenti, T. J. Kipps, D. Mertens, P. Lichter, H. Dohner, S. Stilgenbauer, J. C. Byrd, T. Zenz and C. Plass (2014). "Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia." Cancer Discov 4(3): 348-361. IF 10.143 Woyach. J. A., Furman, R., Liu, T.M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, Z., Li, D., Steggerda, S., Versele, M., Dave, S. S., Zhang, J., Yilmaz, A. S., Jaglowski, S., Blum, K. A., Lozanski, A., Lozanski, G., James, D. F., Barrientos, J., Lichter, P., Stilgenbauer, S., Buggy, J., J., Chang, B.Y., Johnson, A., J., Byrd, J. C. (2014). "Novel Recurring Resistance Mechanism for the Irreversible Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib", N Engl J Med, in press, IF 51.658 _____________________________________ Total Publications derived from the VHI (funding acknowledged) Publications 23 Sum of the Times Cited 238 Cumulative impact factor 262.176 _____________________________________ Original Articles (First- and Last-Authorships, VHI acknowledged) Bladt, T. T., C. Durr, P. B. Knudsen, S. Kildgaard, J. C. Frisvad, C. H. Gotfredsen, M. Seiffert and T. O. Larsen (2013). "Bio-activity and dereplication-based discovery of ophiobolins and other fungal secondary metabolites targeting leukemia cells." Molecules 18(12): 14629-14650. IF 2.428 Dietrich, S., H. Glimm, M. Andrulis, C. von Kalle, A. D. Ho and T. Zenz (2012). "BRAF inhibition in refractory hairy-cell leukemia." N Engl J Med 366(21): 2038-2040. IF 51.658 Dietrich, S., J. Hullein, M. Hundemer, N. Lehners, A. Jethwa, D. Capper, T. Acker, B. K. Garvalov, M. Andrulis, C. Blume, C. Schulte, T. Mandel, J. Meissner, S. Frohling, C. von Kalle, H. Glimm, A. D. Ho and T. Zenz (2013). "Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia." J Clin Oncol 31(19): e300-303. IF 18.038 Dreger, P., A. Schnaiter, T. Zenz, S. Bottcher, M. Rossi, P. Paschka, A. Buhler, S. Dietrich, R. Busch, M. Ritgen, D. Bunjes, M. Zeis, M. Stadler, L. Uharek, C. Scheid, U. Hegenbart, M. Hallek, M. Kneba, N. Schmitz, H. Dohner and S. Stilgenbauer (2013). "TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial." Blood 121(16): 3284-3288. IF 9.060 Eissmann, M., T. Gutschner, M. Hammerle, S. Gunther, M. Caudron-Herger, M. Gross, P. Schirmacher, K. Rippe, T. Braun, M. Zornig and S. Diederichs (2012). "Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development." RNA Biol 9(8): 1076-1087. IF 4.841 Garding, A., N. Bhattacharya, R. Claus, M. Ruppel, C. Tschuch, K. Filarsky, I. Idler, M. Zucknick, M. Caudron-Herger, C. Oakes, V. Fleig, I. Keklikoglou, D. Allegra, L. Serra, S. Thakurela, V. Tiwari, D. Weichenhan, A. Benner, B. Radlwimmer, H. Zentgraf, S. Wiemann, K. Rippe, C. Plass, H. Dohner, P. Lichter, S. Stilgenbauer and D. Mertens (2013). "Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB." PLoS Genet 9(4): e1003373. IF 8.517 Garding, A., N. Bhattacharya, S. Haebe, F. Muller, D. Weichenhan, I. Idler, K. Ickstadt, S. Stilgenbauer and D. Mertens (2013). "TCL1A and ATM are co-expressed in chronic lymphocytic leukemia cells without deletion of 11q." Haematologica 98(2): 269-273. IF 5.935 Gutschner, T., M. Hammerle, M. Eissmann, J. Hsu, Y. Kim, G. Hung, A. Revenko, G. Arun, M. Stentrup, M. Gross, M. Zornig, A. R. MacLeod, D. L. Spector and S. Diederichs (2013). "The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells." Cancer Res 73(3): 1180-1189. IF 8.650 Hammerle, M., T. Gutschner, H. Uckelmann, S. Ozgur, E. Fiskin, M. Gross, B. Skawran, R. Geffers, T. Longerich, K. Breuhahn, P. Schirmacher, G. Stoecklin and S. Diederichs (2013). "Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1 (IGF2BP1)." Hepatology 58(5): 1703-1712. IF 12.003 Hullein, J., A. Jethwa, T. Stolz, C. Blume, L. Sellner, M. Sill, C. Langer, A. Jauch, A. Paruzynski, C. von Kalle, M. Schmidt, H. Glimm and T. Zenz (2013). "Next-generation sequencing of cancer consensus genes in lymphoma." Leuk Lymphoma 54(8): 1831-1835. IF 2.301 Jethwa, A., J. Hullein, T. Stolz, C. Blume, L. Sellner, A. Jauch, M. Sill, A. P. Kater, G. D. te Raa, C. Geisler, M. van Oers, S. Dietrich, P. Dreger, A. D. Ho, A. Paruzynski, M. Schmidt, C. von Kalle, H. Glimm and T. Zenz (2013). "Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia." Br J Haematol 163(4): 496-500. IF 4.942 Knudsen, P. B., B. Hanna, S. Ohl, L. Sellner, T. Zenz, H. Dohner, S. Stilgenbauer, T. O. Larsen, P. Lichter and M. Seiffert (2013). "Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton." Leukemia. IF 10.164 Meier, J., V. Hovestadt, M. Zapatka, A. Pscherer, P. Lichter and M. Seiffert (2013). "Genome-wide identification of translationally inhibited and degraded miR-155 targets using RNA-interacting protein-IP." RNA Biol 10(6): 1018-1029.IF 4.841 Oakes, C. C., R. Claus, L. Gu, Y. Assenov, J. Hullein, M. Zucknick, M. Bieg, D. Brocks, O. Bogatyrova, C. R. Schmidt, L. Rassenti, T. J. Kipps, D. Mertens, P. Lichter, H. Dohner, S. Stilgenbauer, J. C. Byrd, T. Zenz and C. Plass (2014). "Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia." Cancer Discov 4(3): 348-361. IF 10.143 Schnaiter, A., P. Paschka, M. Rossi, T. Zenz, A. Bühler, D. Winkler, M. Cazzola, K. Döhner, J. Edelmann, D. Mertens, S. Kless, S. Mack, R. Busch, M. Hallek, H. Döhner and S. Stilgenbauer (2013). "NOTCH1, SF3B1 and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG." Blood.IF 9.060 Schulz, A., C. Durr, T. Zenz, H. Dohner, S. Stilgenbauer, P. Lichter and M. Seiffert (2013). "Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment." Blood 121(13): 2503-2511. IF 9.060 Seifert, M., L. Sellmann, J. Bloehdorn, F. Wein, S. Stilgenbauer, J. Durig and R. Kuppers (2012). "Cellular origin and pathophysiology of chronic lymphocytic leukemia." J Exp Med 209(12): 2183-2198. IF 13.214 Sill M, Hielscher T, Becker N, Zucknick M. “c060: Extended Inference with Lasso and Elastic-Net Regularized Cox and Generalized Linear Models”. Journal of Statistical Software [accepted November 2013]. http://CRAN.R-project.org/package=c060 IF 4.910 Original Articles (Co-Authorship, VHI acknowledged) Woyach. J. A., Furman, R., Liu, T.M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, Z., Li, D., Steggerda, S., Versele, M., Dave, S. S., Zhang, J., Yilmaz, A. S., Jaglowski, S., Blum, K. A., Lozanski, A., Lozanski, G., James, D. F., Barrientos, J., Lichter, P., Stilgenbauer, S., Buggy, J., J., Chang, B.Y., Johnson, A., J., Byrd, J. C. (2014). "Novel Recurring Resistance Mechanism for the Irreversible Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib", N Engl J Med, in press, IF 51.658 Review Articles (VHI acknowledged) Gutschner, T. and S. Diederichs (2012). "The hallmarks of cancer: a long non-coding RNA point of view." RNA Biol 9(6): 703-719. IF 4.841 Gutschner, T., M. Hammerle and S. Diederichs (2013). "MALAT1 -- a paradigm for long noncoding RNA function in cancer." J Mol Med (Berl) 91(7): 791-801. IF 4.768 Schnaiter, A. and S. Stilgenbauer (2013). "17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach." Hematol Oncol Clin North Am 27(2): 289-301. IF 2.084 Zenz, T., J. G. Gribben, M. Hallek, H. Dohner, M. J. Keating and S. Stilgenbauer (2012). "Risk categories and refractory CLL in the era of chemoimmunotherapy." Blood 119(18): 4101-4107. IF 9.060 Patent Joint Invention Roche and University Hospital Ulm, "Predictive marker for cancer treatment", where NOTCH1 mutation predicts for response to treatment with Rituximab. Published 08/05/14, WO 2014/068133 A1 (PCT-Procedure=1rst Application) Inventors: DÖHNER HARTMUT, DE ; HALLEK MICHAEL, DE ; KLEIN CHRISTIAN, DE ; STILGENBAUER STEPHAN, DE ; UMA A PABLE, DE Anmelder:HOFFMANN LA ROCHE, CH ; HOFFMANN LA ROCHE, US ; UNIV ZU KOELN, DE ; UNIVERSITAETSKLINIKUM ULM, DE Priority: EP12191323 (European Prior Application) Date of priority 05.11.2012 |